Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Raised by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 312,216 shares of the biopharmaceutical company’s stock after buying an additional 41,292 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Alnylam Pharmaceuticals were worth $100,552,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $27,000. Bessemer Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares during the period. Ameritas Advisory Services LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $42,000. Washington Trust Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 61 shares during the period. Finally, Larson Financial Group LLC boosted its position in shares of Alnylam Pharmaceuticals by 77.7% during the first quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 87 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 1.0%

Alnylam Pharmaceuticals stock opened at $464.95 on Tuesday. The stock has a market capitalization of $60.95 billion, a PE ratio of -188.24 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a 50 day simple moving average of $452.27 and a 200-day simple moving average of $347.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several analyst reports. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Barclays boosted their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, Raymond James Financial began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price objective for the company. Twenty-four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $457.08.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares in the company, valued at approximately $11,405,673.55. This trade represents a 8.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president owned 20,221 shares of the company’s stock, valued at $9,129,377.08. The trade was a 13.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock valued at $44,160,261 in the last ninety days. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.